Neurocrine Biosciences (NBIX) Operating Margin (2016 - 2025)
Historic Operating Margin for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 26.18%.
- Neurocrine Biosciences' Operating Margin rose 35600.0% to 26.18% in Q4 2025 from the same period last year, while for Dec 2025 it was 21.64%, marking a year-over-year decrease of 25800.0%. This contributed to the annual value of 21.64% for FY2025, which is 25800.0% down from last year.
- Neurocrine Biosciences' Operating Margin amounted to 26.18% in Q4 2025, which was up 35600.0% from 30.07% recorded in Q3 2025.
- In the past 5 years, Neurocrine Biosciences' Operating Margin registered a high of 30.07% during Q3 2025, and its lowest value of 27.16% during Q1 2023.
- In the last 4 years, Neurocrine Biosciences' Operating Margin had a median value of 21.74% in 2021 and averaged 18.29%.
- Per our database at Business Quant, Neurocrine Biosciences' Operating Margin skyrocketed by 464300bps in 2024 and then plummeted by -151500bps in 2025.
- Neurocrine Biosciences' Operating Margin (Quarter) stood at 15.03% in 2021, then surged by 94bps to 29.17% in 2023, then decreased by -22bps to 22.62% in 2024, then increased by 16bps to 26.18% in 2025.
- Its Operating Margin stands at 26.18% for Q4 2025, versus 30.07% for Q3 2025 and 21.18% for Q2 2025.